Tag
Applying safety-focused, modernized eligibility criteria to historical AML trials increased patient eligibility from a median of 48% to 84% and reduced racial/ethnic disparities, suggesting pragmatic pathways to improve enrollment and repre
Non-proportional hazards in hepatocellular carcinoma immunotherapy trials can distort interim and final survival outcomes. Employing tailored statistical strategies ensures robust, clinically meaningful analyses and informed decision-making
The Score of Integrated Balance in Ataxia (SIBA) is a newly developed digital composite score that accurately measures standing and walking balance in spinocerebellar ataxia, enabling smaller, more efficient clinical trials with improved se
AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.
A secondary analysis of four randomized trials reveals that additional behavioral therapy does not significantly improve opioid abstinence, retention, or functional outcomes when added to buprenorphine and medical management in opioid use d
Venous and arterial thrombotic events in cancer patients are underreported in clinical trials, impairing risk assessment and prevention strategies. Uniform and comprehensive reporting is imperative to improve patient outcomes and guide ther
This review synthesizes 10 years of sulforaphane (SFN) research, highlighting its pharmacology, clinical trial outcomes, and emerging therapeutic prospects across cancer, metabolic, renal, neurodevelopmental, and cardiovascular disorders.
This comprehensive review synthesizes evidence on Tongxinluo’s mechanisms and clinical benefits in myocardial infarction, acute coronary syndrome, and ischemia, highlighting patient subgroup analyses and current gaps in clinical evidence.
This review synthesizes clinical and mechanistic evidence on Ashwagandha, highlighting its adaptogenic, neuropsychiatric, metabolic, and immunomodulatory effects, with insights from RCTs and meta-analyses.
Recent randomized and mechanistic studies provide a nuanced view: metformin shows plausible anti‑aging mechanisms and microbiome‑linked cognitive associations, but randomized trials report no clear anti‑cancer or anti‑senescence effects in
Low-dose IL-2 immunotherapy demonstrates broad, disease-modifying effects by selectively expanding regulatory T cells (Tregs), offering a promising strategy across diverse diseases including autoimmunity, neurodegeneration, metabolic dysfun
This article demystifies key clinical trial efficacy endpoints in oncology, including OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR, providing clinicians with a practical guide to their definitions, roles, and interpretation.
AI offers transformative potential for clinical trials, but realizing its value demands a robust, stakeholder-driven framework to guide adoption and assess impact across the trial lifecycle.
Phase 3 studies demonstrate guselkumab’s efficacy and safety as induction and maintenance therapy for moderate-to-severe Crohn’s disease and ulcerative colitis, with superiority over placebo and favorable safety profiles.
As-needed albuterol–budesonide significantly reduces severe exacerbations in mild asthma compared to albuterol alone, with comparable safety. Two pivotal trials confirm efficacy across lung function and exacerbation outcomes.
Three major Chinese trials examine intravenous and intra-arterial tenecteplase as adjuncts to thrombectomy in acute large-vessel occlusion stroke, revealing functional benefit with intravenous use before thrombectomy but not after reperfusi
Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.
Norovirus vaccines show promise in clinical trials, but scientific and logistical challenges remain. No approved vaccine exists yet, though novel approaches, including oral pills, are advancing development.
